BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27705936)

  • 1. Meta-analysis of gene expression and integrin-associated signaling pathways in papillary renal cell carcinoma subtypes.
    Zhang K; Lee HM; Wei GH; Manninen A
    Oncotarget; 2016 Dec; 7(51):84178-84189. PubMed ID: 27705936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
    Marsaud A; Dadone B; Ambrosetti D; Baudoin C; Chamorey E; Rouleau E; Lefol C; Roussel JF; Fabas T; Cristofari G; Carpentier X; Michiels JF; Amiel J; Pedeutour F
    Genes Chromosomes Cancer; 2015 Jun; 54(6):369-82. PubMed ID: 25820192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways.
    Wala SJ; Karamchandani JR; Saleeb R; Evans A; Ding Q; Ibrahim R; Jewett M; Pasic M; Finelli A; Pace K; Lianidou E; Yousef GM
    Mol Oncol; 2015 Oct; 9(8):1667-77. PubMed ID: 26051997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
    Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
    Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity-a comparative study with papillary renal cell carcinoma.
    Kim SS; Cho YM; Kim GH; Kee KH; Kim HS; Kim KM; Kim JH; Choi C
    Mod Pathol; 2020 Apr; 33(4):690-699. PubMed ID: 31953522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinoma.
    Wang Y; Tian X; Zhu SX; Xu WH; Anwaier A; Su JQ; Gan HL; Qu YY; Zhao JY; Zhang HL; Ye DW
    World J Surg Oncol; 2023 Mar; 21(1):98. PubMed ID: 36927438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification.
    Zhou M; Yang XJ; Lopez JI; Shah RB; Hes O; Shen SS; Li R; Yang Y; Lin F; Elson P; Sercia L; Magi-Galluzzi C; Tubbs R
    Am J Surg Pathol; 2009 Dec; 33(12):1840-9. PubMed ID: 19898225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological, immunohistochemical, and genomic analyses of papillary renal neoplasm with reverse polarity.
    Kiyozawa D; Kohashi K; Takamatsu D; Yamamoto T; Eto M; Iwasaki T; Motoshita J; Shimokama T; Kinjo M; Oshiro Y; Yonemasu H; Oda Y
    Hum Pathol; 2021 Jun; 112():48-58. PubMed ID: 33811832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.
    Furge KA; Chen J; Koeman J; Swiatek P; Dykema K; Lucin K; Kahnoski R; Yang XJ; Teh BT
    Cancer Res; 2007 Apr; 67(7):3171-6. PubMed ID: 17409424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.
    Saleeb RM; Farag M; Lichner Z; Brimo F; Bartlett J; Bjarnason G; Finelli A; Rontondo F; Downes MR; Yousef GM
    Mol Oncol; 2018 Oct; 12(10):1673-1688. PubMed ID: 29896907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality.
    Mejean A; Hopirtean V; Bazin JP; Larousserie F; Benoit H; Chrétien Y; Thiounn N; Dufour B
    J Urol; 2003 Sep; 170(3):764-7. PubMed ID: 12913693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis.
    Saleeb RM; Brimo F; Farag M; Rompré-Brodeur A; Rotondo F; Beharry V; Wala S; Plant P; Downes MR; Pace K; Evans A; Bjarnason G; Bartlett JMS; Yousef GM
    Am J Surg Pathol; 2017 Dec; 41(12):1618-1629. PubMed ID: 28984673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma.
    Singh NP; Vinod PK
    Mol Genet Genomics; 2020 May; 295(3):807-824. PubMed ID: 32185457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression pattern of Von Hippel-Lindau tumor suppressor protein, MET proto-oncogene, and TFE3 transcription factor oncoprotein in renal cell carcinoma in Upper Egypt.
    Nagi FM; Omar AA; Mostafa MG; Mohammed EA; Abd-Elwahed Hussein MR
    Ultrastruct Pathol; 2011 Apr; 35(2):79-86. PubMed ID: 21299348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.
    Polifka I; Agaimy A; Herrmann E; Spath V; Trojan L; Stöckle M; Becker F; Ströbel P; Wülfing C; Schrader AJ; Barth P; Staehler M; Stief C; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Höfler H; Haferkamp A; Geppert CI; Stöhr C; Hartmann A;
    Hum Pathol; 2019 Jan; 83():212-223. PubMed ID: 30121370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.
    Liu K; Ren Y; Pang L; Qi Y; Jia W; Tao L; Hu Z; Zhao J; Zhang H; Li L; Yue H; Han J; Liang W; Hu J; Zou H; Yuan X; Li F
    Int J Clin Exp Pathol; 2015; 8(7):8311-35. PubMed ID: 26339402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative transcriptional and functional profiling of clear cell and papillary renal cell carcinoma.
    Diegmann J; Tomiuk S; Sanjmyatav J; Junker K; Hindermann W; von Eggeling F
    Int J Mol Med; 2006 Sep; 18(3):395-403. PubMed ID: 16865223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLUT1, MCT1/4 and CD147 overexpression supports the metabolic reprogramming in papillary renal cell carcinoma.
    Almeida LMCA; Silva R; Cavadas B; Lima J; Pereira L; Soares P; Sobrinho-Simões M; Lopes JM; Máximo V
    Histol Histopathol; 2017 Oct; 32(10):1029-1040. PubMed ID: 28028797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.